Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715042 | 0.83 | LMNA (0.54) | ROCK2SMN1; SMN2 | |
| SCHEMBL14714737 | 0.83 | KLKB1 (0.51) | MEN1KMT2AROCK2KLKB1KDM1A | |
| SCHEMBL14715281 | 0.83 | HRH3 (0.42) | HRH3KMT2APPARGROCK2KLKB1 | |
| SCHEMBL14714539 | 0.83 | HPGDS (0.42) | HRH3HSD17B10PPARGROCK2ALDH1A1 | |
| SCHEMBL14715019 | 0.83 | HRH3 (0.42) | HRH3HSD17B10EGLN2PPARGALDH1A1 | |
| SCHEMBL14715228 | 0.81 | HRH3 (0.41) | HRH3PPARGROCK2SMN1; SMN2GAA | |
| SCHEMBL14715195 | 0.81 | TSHR (0.57) | MEN1KMT2AROCK2SMN1; SMN2HDAC1 | |
| SCHEMBL14715049 | 0.81 | PPARG (0.51) | HRH3PPARGGAA | |
| SCHEMBL14715425 | 0.80 | PPARG (0.50) | HRH3MEN1KMT2APPARG | |
| SCHEMBL14714981 | 0.79 | ANPEP (0.49) | HRH3PPARGGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| EP-2562155-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | HRH3 1334/4885MEN1 4264/4885KMT2A 361/4885 |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | HRH3 1334/4885MEN1 4264/4885KMT2A 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.